Comparative Pharmacology
Head-to-head clinical analysis: CALCITRIOL versus CALDEROL.
Head-to-head clinical analysis: CALCITRIOL versus CALDEROL.
CALCITRIOL vs CALDEROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcitriol, the active form of vitamin D, binds to vitamin D receptors (VDR) in target tissues, modulating gene transcription. It increases intestinal calcium and phosphate absorption, enhances renal tubular reabsorption of calcium, and promotes bone mineralization by stimulating osteoblast activity.
Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.
0.25-0.5 mcg orally once daily, may increase by 0.25 mcg/day at 4-8 week intervals; maximum 2 mcg/day.
Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.
None Documented
None Documented
Clinical Note
moderateCalcitriol + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Calcitriol."
Clinical Note
moderateCalcitriol + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Calcitriol."
Clinical Note
moderateCalcitriol + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Calcitriol."
Clinical Note
moderateCalcitriol + Fluconazole
5–8 hours (terminal) in normal renal function; prolonged up to 18–24 hours in chronic kidney disease (CKD) due to reduced clearance.
Terminal elimination half-life is approximately 20-30 hours; clinically, steady-state is achieved within 5-7 days.
Renal (fecal after biliary excretion of metabolites): ~10% unchanged in urine; ~70% as metabolites in feces via bile.
Primarily fecal (biliary) as unchanged drug and metabolites (approx. 80%); renal excretion accounts for less than 20%.
Category A/B
Category C
Vitamin D Analog
Vitamin D Analog
"The metabolism of Fluconazole can be decreased when combined with Calcitriol."